Thousand Oaks, CA, United States of America

Qingping Zeng

USPTO Granted Patents = 20 (Patent Applications = 3)

CIPO Patents = 4 (Patent Applications = 2)

EPO Patents = 5 (Patent Applications = 9)

Average Co-Inventor Count = 5.7

ph-index = 8

Forward Citations = 146(Granted Patents)

Company Filing History:

Fosun Orinove Pharmatech, Inc.

patents

4. 2 out of 21

Tolero Pharmaceuticals, Inc.

patents

5. 2 out of 4

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

where one patent can have more than one assignee

Years Active: 2008-2022

Loading Chart...

20 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11337956 - IRE-1α inhibitors (2022-05-24),

2. 10357475 - IRE-1α inhibitors (2019-07-23),

3. 9981901 - IRE-1α inhibitors (2018-05-29),

4. 9867803 - IRE-1α inhibitors (2018-01-16),

5. 9856266 - IRE-1alpha inhibitors (2018-01-02),

6. 9714247 - Multiple kinase pathway inhibitors (2017-07-25),

7. 9693992 - IRE-1α inhibitors (2017-07-04),

8. 9493454 - Multiple kinase pathway inhibitors (2016-11-15),

9. 9493435 - IRE-1α inhibitors (2016-11-15),

10. 9241942 - IRE-1α inhibitors (2016-01-26),

11. 9040714 - IRE-1α inhibitors (2015-05-26),

12. 8614253 - IRE-1α inhibitors (2013-12-24),

13. 8084479 - Thiazole compounds and methods of use (2011-12-27),

14. 7919514 - Thiadiazole compounds and methods of use (2011-04-05),

15. 7919504 - Thiadiazole modulators of PKB (2011-04-05),

Title: Inventor Profile: Qingping Zeng

Introduction

Qingping Zeng, based in Thousand Oaks, CA, is a prominent inventor with an impressive portfolio of 20 patents. His work primarily focuses on innovative compounds that play a critical role in medical treatments associated with the unfolded protein response, making significant strides in pharmaceutical science.

Latest Patents

Among his latest contributions to the field are patents related to IRE-1α inhibitors. These compounds are designed to directly inhibit IRE-1α activity in vitro and include prodrugs and pharmaceutically acceptable salts. They are particularly valuable for treating diseases linked with the unfolded protein response or regulated IRE1-dependent decay (RIDD). Furthermore, these compounds can be utilized as standalone agents or combined with other therapies to enhance treatment efficacy.

Career Highlights

Qingping has made significant contributions throughout his career, with notable positions at leading biotech firms such as Amgen Inc. and Mannkind Corporation. His expertise in developing innovative therapeutic solutions has positioned him as a vital asset in these organizations.

Collaborations

Throughout his career, Qingping has worked alongside distinguished professionals, including John Bruce Patterson and Warren Stanfield Wade. These collaborations have fostered a dynamic environment for the exchange of ideas and enhancements in research methodologies, ultimately driving innovations in the industry.

Conclusion

Qingping Zeng's impactful inventions and collaborations exemplify the critical role that inventors play in advancing medical treatments. His dedication to research and development continues to open new avenues in healthcare, paving the way for more effective therapeutic options in the future.

This text is generated by artificial intelligence and may not be accurate.